A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT07412704

Public ClinicalTrials.gov record NCT07412704. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 3, 2026, 7:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).

Study identification

NCT ID: NCT07412704
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 84 participants

Conditions and interventions

Conditions

Arthritis, Rheumatoid

Interventions

BMS-986528 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 14, 2026
Primary completion: Oct 29, 2029
Completion: Sep 1, 2030
Last update posted: Aug 23, 2026

2026 – 2030

United States locations

U.S. sites: 11
U.S. states: 7
U.S. cities: 10

Facility	City	State	ZIP	Site status
Local Institution - 0068	La Jolla	California	92037	Not yet recruiting
Local Institution - 0070	Loma Linda	California	92354	Not yet recruiting
Local Institution - 0069	Palo Alto	California	94304-2210	Not yet recruiting
Local Institution - 0050	Aurora	Colorado	80045	Not yet recruiting
Colorado Blood Cancer Institute	Denver	Colorado	80218	Recruiting
Local Institution - 0055	South Miami	Florida	33143	Not yet recruiting
Local Institution - 0081	New York	New York	10016	Not yet recruiting
Local Institution - 0079	New York	New York	10029	Not yet recruiting
Local Institution - 0066	Portland	Oregon	97239	Not yet recruiting
Local Institution - 0071	Philadelphia	Pennsylvania	19107	Not yet recruiting
Local Institution - 0051	DeSoto	Texas	75115	Withdrawn

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07412704, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 23, 2026 · Synced Sep 3, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07412704 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →